Schrodinger, Inc. (SDGR) FY2026 Q2 P&L / Income Statement

Schrodinger, Inc. (SDGR) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

Total revenues

58,889,000 US dollars

Total cost of revenues

26,457,000 US dollars

Gross profit

32,432,000 US dollars

Total operating expenses

73,979,000 US dollars

Loss from operations

negative 41,547,000 US dollars

Total other income

48,894,000 US dollars

Income (loss) before income taxes

7,347,000 US dollars

Income tax expense

1,372,000 US dollars

Net income (loss)

5,975,000 US dollars

Software products and services revenue

32,544,000 US dollars

Drug discovery revenue

22,986,000 US dollars

Contribution revenue

3,359,000 US dollars

Software products and services cost of revenue

9,449,000 US dollars

Drug discovery cost of revenue

15,794,000 US dollars

Contribution cost of revenue

1,214,000 US dollars

Research and development

40,998,000 US dollars

Sales and marketing

10,266,000 US dollars

General and administrative (includes related party expense of $165, $109, $330 and $218)

22,715,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.